PT-141, known clinically as bremelanotide, is a melanocortin receptor agonist whose phase 2 and phase 3 trial papers report nausea, flushing and injection-site reactions as the most frequently recorded adverse events, alongside a measurable transient rise in blood pressure shortly after administration. The phase 3 trial program used subcutaneous injection in adult women with a defined sexual-function diagnosis, while earlier phase 2 work tested both intranasal and subcutaneous delivery at several amounts.
| Key fact | Value | Source |
|---|---|---|
| Receptor target | Melanocortin-4 receptor agonist, cyclic heptapeptide derived from alpha-MSH | Mechanism described across the cited trial papers |
| Phase 3 trial design | Two identically designed randomized, double-blind, placebo-controlled trials in premenopausal women (RECONNECT) | Kingsberg et al. 2019, Obstet Gynecol |
| Most frequently recorded adverse events in the phase 3 program | Nausea, flushing, injection-site reactions and headache, each reported at a specific frequency in the trial papers | Kingsberg et al. 2019; Dhillon and Keam 2019, Drugs |
| Blood-pressure finding | Transient increases in blood pressure and decreases in heart rate recorded in the hours after administration | Kingsberg et al. 2019; Dhillon and Keam 2019 |
| Earlier program route | An intranasal formulation was studied before the program moved to subcutaneous injection for the phase 2b and phase 3 trials | Diamond et al. 2006, J Sex Med |
What amounts were studied across the bremelanotide trials?
The published program moved through several trial designs before settling on the amount and route used in the phase 3 trials. Early subcutaneous work in men established a pharmacokinetic and pharmacodynamic profile across an ascending series of amounts, an early trial in women tested an intranasal formulation, and a phase 2b dose-finding trial in premenopausal women compared several subcutaneous amounts against placebo before a single amount was carried forward into the phase 3 RECONNECT trials. The specific amount and route used in each trial are reported in the Study table below exactly as each paper states them.
What adverse events were reported in the phase 3 trials?
The RECONNECT phase 3 program pooled two identically designed trials in premenopausal women with a diagnosed sexual-desire condition. The trial publication and the subsequent regulatory review paper report nausea as the most common adverse event, affecting roughly four in ten subjects on active treatment, with flushing recorded in roughly one in five, injection-site reactions in roughly one in eight, and headache in roughly one in nine. These figures describe tolerability findings from the pooled phase 3 dataset as printed in the trial and review publications; they are not a general statement about how often any individual subject experiences an event, since trial-level frequencies describe the study population as a whole.
What did the earlier phase 2 work report for adverse events?
The phase 2b dose-finding trial in premenopausal women compared multiple subcutaneous amounts against placebo and reported that nausea and flushing rose with the amount administered, with the highest amount tested in that trial showing the highest rates of both events among the active-treatment groups. The earlier intranasal study in women with sexual arousal concerns also recorded nausea and flushing as the most frequent events, alongside the pharmacodynamic and blood-pressure monitoring that informed the later decision to carry the program forward with subcutaneous dosing rather than the intranasal route tested first.
What was reported about blood pressure?
Blood-pressure monitoring is a recurring tolerability finding across the bremelanotide trial papers. The phase 3 trial publications and the subsequent regulatory review describe a transient increase in blood pressure and a transient decrease in heart rate in the hours following subcutaneous administration, an effect consistent with melanocortin receptor activity on the cardiovascular system. Because of this finding, the trial and review publications flag uncontrolled hypertension and known cardiovascular disease as conditions that affected how the studies were designed and how the compound was later reviewed for regulatory approval. This blood-pressure effect, along with the nausea and flushing findings, is the main tolerability signal that distinguishes bremelanotide from other melanocortin receptor agonists tested in the broader research literature.
How did tolerability differ between the intranasal and subcutaneous formulations?
The earlier intranasal formulation and the later subcutaneous formulation were not tested head to head for adverse events in a single trial, so the comparison in the literature is across separate studies rather than within one randomized design. Both formulations recorded nausea and flushing as leading events in their respective trials, and the program's shift toward subcutaneous administration for the phase 2b and phase 3 trials reflects pharmacokinetic and tolerability considerations described in the early trial publications rather than a single adverse-event figure that was directly compared between the two routes.
| Study | Model and n | Amount and route (as reported) | Endpoint | Finding |
|---|---|---|---|---|
| Rosen et al. 2004 (PubMed) | Human, healthy men and men with a sexual-function diagnosis, ascending-amount design | Subcutaneous injection, amount escalated across sequential cohorts as reported in the paper | Pharmacokinetics, pharmacodynamics, adverse events recorded | Nausea and flushing were the most frequently recorded adverse events, rising with the amount administered |
| Diamond et al. 2006 (PubMed) | Human, premenopausal women with a sexual arousal diagnosis | Intranasal administration, amount reported in the paper | Subjective sexual response measures, adverse events recorded | Nausea and flushing were recorded as the leading adverse events; subjective arousal measures improved versus placebo |
| Clayton et al. 2016 (PubMed) | Human, premenopausal women, randomized placebo-controlled dose-finding, multiple amounts compared | Subcutaneous injection, several amounts compared against placebo as reported in the paper | Sexual function endpoints as defined in the trial, adverse events recorded | Nausea and flushing rates increased with the amount administered; one amount was selected to carry forward into phase 3 |
| Kingsberg et al. 2019, RECONNECT I and II (PubMed) | Human, two pooled randomized, double-blind, placebo-controlled phase 3 trials in premenopausal women | Subcutaneous injection, as-needed use at a fixed amount as reported in the paper | Sexual function endpoints as defined in the trial, adverse events recorded, vital signs | Nausea, flushing, injection-site reactions and headache were the most frequently reported adverse events; transient blood-pressure increases were recorded |
| Simon et al. 2019 (PubMed) | Human, open-label extension of the phase 3 program | Subcutaneous injection continued at the phase 3 amount over an extended period as reported in the paper | Long-term adverse events and tolerability | Adverse event pattern over the extension period was consistent with the pooled phase 3 trials |
| Dhillon and Keam 2019 (PubMed) | Regulatory review article summarizing the phase 3 program | Not applicable; review of the subcutaneous phase 3 program | Summary of efficacy and adverse event data supporting regulatory approval | Confirmed nausea, flushing, injection-site reactions, headache and transient blood-pressure increases as the leading tolerability findings |
How were adverse events defined and recorded in these trials?
The phase 2 and phase 3 publications use standard clinical-trial adverse event methodology: a treatment-emergent adverse event is any event that started or worsened after the first dose in the trial period, and investigators recorded each event by system organ class alongside its onset timing relative to dosing and its outcome. Nausea, flushing, injection-site reactions and headache were among the events specifically collected and tabulated as treatment-emergent adverse events rather than being drawn from open-ended participant reports, which is why the trial papers and the regulatory review article can state specific frequencies for each event rather than a general tolerability impression. Vital-sign readings, including blood pressure and heart rate, were collected on a defined schedule relative to dosing in the later trials, which is how the transient blood-pressure finding was captured with enough precision to report a timing window rather than only a yes-or-no safety flag.
How is PT-141 handled in a research setting?
Lyophilized PT-141 is reconstituted with an appropriate diluent shortly before bench use and kept cold between uses to limit degradation. The volume and concentration calculations follow the same approach used for other lyophilized research peptides, covered step by step in reconstituting lyophilized peptides, and the identity and purity data that should accompany a research lot are explained in how to read a peptide certificate of analysis.
For background on PT-141's melanocortin receptor pharmacology and where it sits among related research peptides, see what is PT-141 (bremelanotide), and for the general physical chemistry behind why a trial program might test more than one route before settling on one, see peptide bioavailability by route. PT-141 research material is available as PT-141 for laboratory use.
Frequently asked questions
What was the single most frequently reported adverse event in the phase 3 trials?
Nausea was reported as the most frequent adverse event in the pooled RECONNECT phase 3 trials, followed by flushing, injection-site reactions and headache.
Did the trials report serious cardiovascular events?
The trial and review publications describe a transient rise in blood pressure and a transient fall in heart rate after administration as the main cardiovascular tolerability signal, and flag uncontrolled hypertension and cardiovascular disease as relevant exclusion considerations in the trial designs and subsequent regulatory review.
Why did the program move from intranasal to subcutaneous delivery?
The early intranasal trial established a pharmacodynamic signal but the later dose-finding and phase 3 work moved to subcutaneous injection, a route change the original publications attribute to the pharmacokinetic and tolerability profile observed across the earlier studies rather than to a single adverse-event figure.
Did adverse event rates change with the amount administered?
Yes, in the phase 2b dose-finding trial nausea and flushing rates rose as the amount administered increased across the compared groups, which is part of why a single amount was selected to carry forward into the phase 3 trials rather than the highest amount tested.
Were the adverse events similar in the long-term extension study?
The published open-label extension reported an adverse event pattern consistent with the pooled phase 3 trials over the longer treatment window, without a new leading event emerging in that extension.
Is PT-141 the same compound referred to as bremelanotide in these papers?
Yes. PT-141 is the research designation used in earlier pharmacology literature, and bremelanotide is the name used once the compound moved through later-stage trials and regulatory review.
References
- Rosen RC, Diamond LE, Earle DC, Shadiack AM, Molinoff PB. Evaluation of the safety, pharmacokinetics and pharmacodynamic effects of subcutaneously administered PT-141, a melanocortin receptor agonist, in healthy male subjects and in patients with erectile dysfunction. Int J Impot Res. 2004;16(2):135-142. PubMed PMID 14743185.
- Diamond LE, Earle DC, Heiman JR, Rosen RC, Perelman MA, Harning R. An effect on the subjective sexual response in premenopausal women with sexual arousal disorder by bremelanotide (PT-141), a melanocortin receptor agonist. J Sex Med. 2006;3(4):628-638. PubMed PMID 16839321.
- Clayton AH, Althof SE, Kingsberg S, et al. Bremelanotide for female sexual dysfunctions in premenopausal women: a randomized, placebo-controlled dose-finding trial. Womens Health (Lond). 2016;12(3):325-337. PubMed PMID 27105075.
- Kingsberg SA, Clayton AH, Portman D, et al. Bremelanotide for the treatment of hypoactive sexual desire disorder: two randomized phase 3 trials. Obstet Gynecol. 2019;134(5):899-908. PubMed PMID 31599825.
- Simon JA, Kingsberg SA, Portman D, et al. Long-term safety and efficacy of bremelanotide for hypoactive sexual desire disorder. Obstet Gynecol. 2019;134(5):909-917. PubMed PMID.
- Dhillon S, Keam SJ. Bremelanotide: first approval. Drugs. 2019;79(16):1599-1606. PubMed PMID 31637684.
Research use only. Homegrown Peptides products are for laboratory research and are not for human or animal use. Nothing in this article is medical advice.



